Other · developed by SAb Biotherapeutics
SAB-142 is an intravenously administered investigational agent studied in type 1 diabetes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07670650 | Phase 3 | Type 1 Diabetes (T1D) | Not yet recruiting | SABS |
| NCT07187531 | Phase 2 | Type 1 Diabetes | Recruiting | SABS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Type 1 DiabetesType 1 Diabetes (T1D)
Updated Nov 1, 2026. Something wrong or missing? Report it on the SABS page.
See SABS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SABS catalysts and pipeline →